Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836437 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL24393470 | 0.88 | HDAC6 (0.46) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL25853943 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL25854290 | 0.84 | EHMT2 (0.44) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL16132816 | 0.84 | ALDH1A1 (0.54) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL1395632 | 0.84 | ALDH1A1 (0.54) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL19193751 | 0.79 | EHMT2 (0.44) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL24336889 | 0.78 | KMT2A (0.52) | HPGDKMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL18958956 | 0.78 | LMNA (0.40) | SMN1; SMN2HPGDHSD17B10KMT2AMEN1 | |
| SCHEMBL31005453 | 0.77 | KMT2A (0.46) | SMN1; SMN2HPGDKMT2AMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341050-A1 | Cytotoxic agents containing novel potent taxanes and their therapeutic use | ImmunoGen, Inc. (US) | 2011-07-06 | — | — | EP | disclosed |
| US-7585857-B2 | Cytotoxic agents comprising taxanes and their therapeutic use | IMMUNOGEN INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7550609-B2 | Cytotoxic agents comprising taxanes and their therapeutic use | IMMUNOGEN INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7528130-B2 | Cytotoxic agents comprising taxanes and their therapeutic use | IMMUNOGEN INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7495114-B2 | Cytotoxic agents containing novel potent taxanes and their therapeutic use | IMMUNOGEN INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7476669-B2 | Cytotoxic agents comprising taxanes and their therapeutic use | IMMUNOGEN INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7414073-B2 | Cytotoxic agents containing novel potent taxanes and their therapeutic use | IMMUNOGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7390898-B2 | Cytotoxic agents containing novel potent taxanes and their therapeutic use | IMMUNOGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080027130-A1 | CYTOTOXIC AGENTS COMPRISING TAXANES AND THEIR THERAPEUTIC USE | IMMUNOGEN INC. | 2008-01-31 | — | — | US | disclosed |
| EP-1534674-A4 | CYTOTOXIC AGENTS CONTAINING NOVEL POTENT TAXANES AND THEIR THERAPEUTIC USE | IMMUNOGEN INC (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1242438-A1 | CYTOTOXIC AGENTS COMPRISING MODIFIED DOXORUBICINS AND DAUNORUBICINS AND THEIR THERAPEUTIC USE | Immunogen, Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1242401-A1 | CYTOTOXIC AGENTS COMPRISING TAXANES AND THEIR THERAPEUTIC USE | Immunogen, Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6436931-B1 | COMPRISING ONE OR MORE TAXANES LINKED TO A CELL BINDING AGENT SUCH AS MONOCLONAL ANTIBODIES; NOVEL SULFUR-CONTAINING TAXANES | IMMUNOGEN INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020086897-A1 | CYTOTOXIC AGENTS COMPRISING TAXANES AND THEIR THERAPEUTIC USE | IMMUNOGEN, INC. | 2002-07-04 | — | — | US | disclosed |
| US-6372738-B2 | PRODRUG WITH TAXANE AND CELL BINDING AGENT | IMMUNOGEN INC. | 2002-04-16 | — | — | US | disclosed |
| US-20020013485-A1 | Cytotoxic agents comprising taxanes and their therapeutic use | IMMUNOGEN, INC. | 2002-01-31 | — | — | US | disclosed |
| US-6340701-B1 | TAXANES CHEMICALLY LINKED TO CELL BINDING AGENT FOR DELIVERING TO SPECIFIC CELL POPULATION IN TARGETED FASHION | IMMUNOGEN INC | 2002-01-22 | — | — | US | disclosed |
| US-20010036923-A1 | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use | IMMUNOGEN, INC. | 2001-11-01 | — | — | US | disclosed |
| WO-2001049698-A1 | CYTOTOXIC AGENTS COMPRISING MODIFIED DOXORUBICINS AND DAUNORUBICINS AND THEIR THERAPEUTIC USE | IMMUNOGEN, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001038318-A1 | CYTOTOXIC AGENTS COMPRISING TAXANES AND THEIR THERAPEUTIC USE | IMMUNOGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013485-A1 | Cytotoxic agents comprising taxanes and their therapeutic use | TP53, MCL1, TOP1 | SMN1; SMN2 236/4885HPGD 2903/4885HSD17B10 4135/4885 |
| US-20020086897-A1 | CYTOTOXIC AGENTS COMPRISING TAXANES AND THEIR THERAPEUTIC USE | TP53, MCL1, TOP1 | SMN1; SMN2 236/4885HPGD 2903/4885HSD17B10 4135/4885 |
| US-20010036923-A1 | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use | DDB1, MCL1, MTDH | SMN1; SMN2 2008/4885HPGD 4390/4885HSD17B10 3983/4885 |
| US-20080027130-A1 | CYTOTOXIC AGENTS COMPRISING TAXANES AND THEIR THERAPEUTIC USE | TP53, MCL1, TOP1 | SMN1; SMN2 236/4885HPGD 2903/4885HSD17B10 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.